Clinical trials
Other Solid Tumors clinical trials
Below are recruiting other solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,678 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04928612RecruitingPhase 1
CBP-1018 for advanced cancers that no standard treatment helped
This early-phase study tests CBP-1018 in people with advanced solid tumors, such as prostate, kidney, or certain lung cancers. It aims to see how the drug works and whether it’s safe enough to continue studying.
Guangzhou, GuangdongAges 18 years+ - NCT05238792RecruitingPhase 1
Immune cells to treat high-risk solid tumors in children
This trial tests a type of immunotherapy using special white blood cells (T-cells) that are trained to find and attack cancer cells. It is for children and young adults with high-risk solid tumors that have not gone away or have come back after standard treatment.
Washington D.C., District of ColumbiaAges 1–70 - NCT04643418RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors you can’t remove
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
TaipeiAges 18 years+ - NCT04942717Recruiting
Talking about health values with Spanish or English-speaking patients
This study tests an approach for discussing and sharing what patients value about their health, and adapting it for Latinx communities. It involves separate interviews with patients, families/caregivers, and oncology clinicians to improve how the intervention works and is understood.
New York, New YorkAges 21 years+ - NCT05166070RecruitingEarly Phase 1
RD133 for mesothelin-positive tumors after prior treatments
This early-phase study tests RD133, an experimental treatment, in adults whose solid tumors are mesothelin-positive and have come back or not responded to prior standard therapies. It aims to see how well RD133 can control these cancers and what side effects it causes.
Nanjing, JiangsuAges 18 years+ - NCT04685226RecruitingPhase 1/Phase 2
Testing ICP-723 for advanced solid tumors you can’t remove
This trial studies ICP-723 (a new medicine) in people with advanced cancers that cannot be removed with surgery, and in some primary brain (CNS) tumors. It’s an early-phase study (Phase 1/2) to see how the treatment works and how safe it is.
Hefei, AnhuiAges 12 years+ - NCT03810339RecruitingPhase 2
Check a POLE/POLD cancer drug for non–MSI-high tumors
This Phase 2 trial studies toripalimab (JS001), given alone, in people whose tumors have specific POLE or POLD gene mutations but do not have MSI-H/dMMR. If it works, it may help shrink or control advanced solid tumors that have not responded to standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT04219254RecruitingPhase 1/Phase 2
Testing BI-1206 with pembrolizumab for advanced solid cancers
This early-phase trial studies BI-1206 together with pembrolizumab to treat advanced solid tumors. It may be an option if your cancer has progressed after prior anti–PD-1/PD-L1 treatment (or, in some groups, if standard treatments aren’t suitable).
Los Angeles, CaliforniaAges 18 years+ - NCT06973863RecruitingPhase 1
Study of PEP08 for advanced solid tumors with MTAP deletion
This trial tests a new drug called PEP08 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). It might be an option if standard treatments no longer work or cause too many side effects.
Wentworthville, New South WalesAges 18 years+ - NCT06962254RecruitingPhase 1
Imatinib and Trametinib for KRAS-mutated solid tumors
This trial tests a combination of two targeted drugs, imatinib and trametinib, for people with advanced solid tumors that have a specific KRAS mutation (G12X). It may be an option if standard treatments have stopped working or are not available.
Taichung, TaichungAges 20 years+ - NCT07671534RecruitingPhase 2
Metronomic chemotherapy with gemcitabine, mitomycin C, and thalidomide for advanced solid tumors
This trial tests a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in a low, frequent 'metronomic' schedule to treat advanced solid tumors that have already been treated. The goal is to see if this approach can slow or stop tumor growth with fewer side effects.
Santa Monica, CaliforniaAges 18 years+ - NCT06208410RecruitingPhase 1/Phase 2
JS105 plus other treatments for advanced solid tumors
This trial tests a new drug called JS105 combined with other anti-cancer therapies for people with certain advanced breast, ovarian, endometrial, or cervical cancers. It aims to find out if these combinations are safe and effective.
Zhengzhou, HenanAges 18–75 - NCT03739827Recruiting
Study rare solid tumors and collect your health samples
This study follows people (and sometimes family members) connected to rare solid tumors and collects health information and samples (biospecimens). It helps researchers understand how these cancers develop and builds resources for future research, which may benefit you by contributing to better tailored care for rare cancers.
Bethesda, MarylandAges 4 weeks+ - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Atlanta, GeorgiaAges 1–30 - NCT07669415RecruitingPhase 2
LM-168 combined with other treatments for advanced solid tumors
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT00900471Recruiting
Store tissue samples from surgery for suspected solid tumors
This study collects and stores small tissue samples from people who have surgery or a biopsy for a suspected solid (non-blood) tumor. It helps researchers study these cancers for future testing and research.
Winston-Salem, North CarolinaAges 18–120 - NCT07046702Recruiting
PET scan using a new tracer for solid tumors
This study tests whether a new imaging agent called 68Ga-MY6349 can help detect tumors during a PET/CT scan. If you are an adult with a solid tumor (newly diagnosed or already treated), you may be able to take part in this research to see if the new tracer works better than standard imaging.
Xiamen, FujianAges 18 years+ - NCT06239298RecruitingPhase 1/Phase 2
Testing ZG005 plus donafenib for advanced solid tumors
This trial tests two drugs, ZG005 and donafenib, together in people with advanced solid tumors that have not responded to other treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT06081907RecruitingPhase 1/Phase 2
IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
Changsha, HunanAges 18–75 - NCT07268040RecruitingPhase 2
Study of SHR-7787 injection plus other cancer drugs for solid tumors
This trial is testing a new drug, SHR-7787, combined with other cancer treatments for people with advanced solid tumors that cannot be removed by surgery. The goal is to see if this combination can help shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07505069RecruitingEarly Phase 1
PET imaging study for people with solid tumors
This trial is testing a new imaging agent called RT01-89Zr to see if it can help detect solid tumors during PET/CT scans. It involves an injection of the agent followed by imaging, and may offer a more targeted way to visualize tumors.
Wuxi, JiangsuAges 18–75 - NCT04967833RecruitingEarly Phase 1
Testing TIL cell therapy for advanced solid tumors
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
ShanghaiAges 18–75 - NCT07529002Recruiting
New PET scan imaging test for solid tumors
This trial tests a new type of PET scan (a special imaging test) called 89Zr-s-C1 to help detect and monitor solid tumors like melanoma, gastric cancer, or colorectal cancer. The scan may help doctors see tumors more clearly and track whether treatment is working.
Beijing, Beijing MunicipalityAges 15–70 - NCT07229638RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for solid tumors
This study tests a new drug called SHR-9839 given under the skin, combined with other anti-cancer treatments, for people with solid tumors. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70
Hear when a new Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other solid tumors?
- Yes. Clin2 currently lists 1,678 recruiting other solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.